1. Lasorsa F, Rutigliano M, Milella M, d’Amati A, Crocetto F, Pandolfo SD, et al. Ischemia-reperfusion injury in kidney transplantation: mechanisms and potential therapeutic targets. Int J Mol Sci 2024; 25: 4332.
2. Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 2015; 4: 20-27.
3. Chen YS, Tian HX, Rong DC, Wang L, Chen S, Zeng J, et al. ROS homeostasis in cell fate, pathophysiology, and therapeutic interventions. Mol Biomed 2025; 6: 89.
4. An P, An Y, Chen M, Wu L, Wang R. Ischemia-reperfusion injury: molecular mechanisms and therapeutic interventions. MedComm (2020) 2026; 7: e70822.
5. Hasanvand A, Tajdar A, Mohtashami AZ, Haghighatian Z, Goodarzi E, Baharvand PA, et al. Investigating the role of empagliflozin in the pathological progress of ischemia-reperfusion injury in rat kidneys: the involvement of nitric oxide. Adv Pharm Bull 2025; 15: 939-947.
6. Maseko TL, Dlamini NP, Molefe SK. Role of oxidative stress and mitochondrial dysfunction in the pathogenesis of renal ischemia-reperfusion injury. J Adv Biomed Med 2025; 13: 292-310.
7. Chen Y, Li Z, Zhang H, Chen H, Hao J, Liu H, et al. Mitochondrial metabolism and targeted treatment strategies in ischemic-induced acute kidney injury. Cell Death Discov 2024; 10: 69.
8. Rashid H, Jali A, Akhter MS, Abdi SAH. Molecular mechanisms of oxidative stress in acute kidney injury: Targeting the loci by resveratrol. Int J Mol Sci 2024; 25: 3.
9. Pan Y, Zhu J. Mitochondria in renal ischemia-reperfusion injury: From mechanisms to therapeutics. Biomedicines 2026; 14: 310.
10. Artusi I, Rubin M, Cravin G, Cozza G. Ferroptosis in human diseases: Fundamental roles and emerging therapeutic perspectives. Antioxidants (Basel) 2025; 14: 1411.
11. Duo K, Feng X, Tian X, Wang F, Zhao Y, Yu J, et al. Ferroptosis inhibitors: Mechanisms of action and therapeutic potential. Cell Mol Life Sci 2025; 82: 441.
12. Granata S, Votrico V, Spadaccino F, Catalano V, Netti GS, Ranieri E, et al. Oxidative stress and ischemia/reperfusion injury in kidney transplantation: Focus on ferroptosis, mitophagy and new antioxidants. Antioxidants (Basel) 2022; 11: 769.
13. Gulyaeva NV. Glucagon-like peptide-1 receptor agonists are promising for the treatment of brain diseases: An outlook from the perspective of integrative physiology. J Evol Biochem Physiol 2025; 61: 1326-1348.
14. Gaggini M, Sabatino L, Suman AF, Chatzianagnostou K, Vassalle C. Insights into the roles of GLP-1, DPP-4, and SGLT2 at the crossroads of cardiovascular, renal, and metabolic pathophysiology. Cells 2025; 14: 387.
15. Salmanoglu M, Ercan G, Genç HS, Gül SS, Aygün H. GLP-1 receptor agonist exenatide protects against doxorubicin-induced cardiotoxicity through the SIRT1 pathway: An electrocardiographic, 99mTc-PYP scintigraphic, and biochemical study. Medicina (Kaunas) 2026; 62: 143.
16. Fronc K, Listos P, Kasprzak P, Berger M, Słowik T, Kotlińska J, et al. Linagliptin, a selective DPP-4 inhibitor, attenuates ketamine- and diazepam-induced deficits in passive avoidance performance in mice. Brain Sci 2026; 16: 710.
17. Saeedi T, Almikhlafi M, Elbadawy HM, Albadrani MS, Abdel-Rahman RF, Asaad GF, et al. Linagliptin attenuates kidney cancer in rats via AMPK activation and suppression of YAP/TAZ/HIF-1α signaling. Eur J Pharm Sci 2026; 217: 107393.
18. Lee J, Li Y, Cheng JT, Liu IM, Cheng KC. Development of syringaldehyde as an agonist of the GLP-1 receptor to alleviate diabetic disorders in animal models. Pharmaceuticals (Basel) 2024; 17: 538.
19. Haghighatian Z, Goodarzi E, Hadian B, Hasanvand A. Investigating the nitric oxide pathway stimulated by rosuvastatin on the pathological effects of renal ischemia-reperfusion in rats. J Pharm Pharmacol 2026; 78: rgaf097.
20. Goudarzi M, Kalantar H, Fereidoonnezhad M, Kalantar M. Protective effect of gallic acid on mercuric chloride-nephrotoxicity in experimental rats. Nexus of Pathophysiology and Therapeutics (NPT) 2026; 1: 016, 1-13.
21. Cakir M, Polat A, Tekin S, Vardi N, Taslidere E, Duran ZR, et al. The effect of dexmedetomidine against oxidative and tubular damage induced by renal ischemia reperfusion in rats. Ren Fail 2015; 37: 704-708.
22. Mohammadi Jouabadi S, Mokhtari S. Mechanistic clinical pharmacology: Bridging PK-PD modeling, biomarkers, and translational therapeutics. Nexus of Pathophysiology and Therapeutics (NPT) 2026; 1: 006, 1-5.
23. Li X, Wang H, Ma H, Sun J, Luo Y, Qin M, et al. USAG-1 aggravates renal ischemia-reperfusion injury via promoting GPX4 degradation-induced ferroptosis. Cell Death Dis 2026; 17: 646.
24. Tan R, Ge C, Yan Y, Guo H, Han X, Zhu Q, et al. Deciphering ferroptosis in critical care: mechanisms, consequences, and therapeutic opportunities. Front Immunol 2024; 15: 1511015.
25. Qiu Q, Zhou Y, Xia K, Yan Z, Hui Y, Chen Z, et al. Luteoloside attenuates renal ischemia-reperfusion injury by suppressing ferroptosis through disruption of the KEAP1-NRF2 interaction. Free Radic Biol Med 2026; 248: 177-193.
26. Ozhan O, Ekici C, Ates B, Yildiz A, Balcioglu S, Vardi N, et al. N-acetyl cysteine amide mitigates oxidative stress and apoptosis in a rat model of renal ischemia-reperfusion injury. Sci Rep 2026; 16: 6323.
27. Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci 2017; 19: 26.
28. Yaghoubi A, Aghaei Z. Nitric oxide signaling in inflammation and oxidative stress: Mechanistic insights and therapeutic opportunities. Nexus of Pathophysiology and Therapeutics (NPT) 2026; 1: 009, 1-16.
29. Mousavi SE, Davoudi S, Soleimani E. Immunometabolic reprogramming in disease: From energy homeostasis and inflammatory signaling to therapeutic targeting across organ systems. Nexus of Pathophysiology and Therapeutics (NPT) 2026; 1: 013, 1-19.
30. Zhang M, Zheng H, Jin H, Zhu X, Liu S, Chen Y, et al. Regulating SLC7A11/GSH/GPX4 axis by glucose dyshomeostasis to simultaneously promote disulfidptosis, cuproptosis and ferroptosis. Bioact Mater 2025; 54: 744-758.
31. Sahin T. Regulatory effects of plant-derived phenolic compounds on ferroptosis: A novel paradigm in cancer therapy. Pharmedicine J 2026; 3: 1-26.
32. Li X, Yan J, Xu Y, Ling Z, Zhang T, Shao X, et al. Formononetin alleviated cisplatin-induced acute kidney injury by orchestrating renal tubular cell ferroptosis via PI3K/AKT/NRF2 pathway. Front Pharmacol 2026; 17: 1777367.
33. Lai K, Chen Z, Lin S, Ye K, Yuan Y, Li G, et al. The IDH1-R132H mutation aggravates cisplatin-induced acute kidney injury by promoting ferroptosis through disrupting NDUFA1 and FSP1 interaction. Cell Death Differ 2025; 32: 242-255.
34. Pan Y, Wang X, Liu X, Shen L, Chen Q, Shu Q. Targeting ferroptosis as a promising therapeutic strategy for ischemia-reperfusion injury. Antioxidants (Basel) 2022; 11: 2196.
35. Wang W, Chen J, Zhan L, Zou H, Wang L, Guo M, et al. Iron and ferroptosis in kidney disease: Molecular and metabolic mechanisms. Front Immunol 2025; 16: 1531577.
36. Seyed Siamdoust SA, Zaman B, Noorizad S, Alimian M, Barekati M. Comparison of the effect of intercostobrachial nerve block with and without ultrasound guidance on tourniquet pain after axillary block of brachial plexus: A randomized clinical trial. Anesth Pain Med 2023; 13: e134819.
37. Gonzalez ES, Soltani R. Beyond weight loss: Rethinking the clinical pharmacology and medication safety of GLP-1 receptor agonists. Nexus of Integrated Clinical Science (NICS) 2026; 1: 018, 1-6.